Perlegen's mission is to commercialize high-value molecular diagnostics, particularly genetic tests, that provide physicians with information that will significantly improve the clinical decision-making process and ultimately improve patient treatment outcomes.

Our tests are based on discovering and validating genetic variations that predict how patients are likely to respond to medical treatments as well as their susceptibility or predisposition to certain diseases.

MammaPLUS^TM Breast Cancer Risk Stratifier
Perlegen plans to launch its lead product, the MammaPLUS test, in fall 2009.

MammaPLUS is a comprehensive panel of currently-described common genetic variants (single nucleotide polymorphisms, or SNPs) that impact the risk for developing invasive breast cancer. The SNPs are independent, so the contribution of each risk or reference allele is additive.

MammaPLUS stratifies individual genetic plus background/clinical risk for those at moderately elevated risk for non-familial (“sporadic”) breast cancer.

By helping to classify risk levels in accordance with existing published guidelines, MammaPLUS should help allocate resources more efficiently and improve patient care.

Breast cancer: Risk and diagnosis

Recent News
June 4, 2009
Perlegen Lab Receives CLIA License
Perlegen Clinical Laboratory Services facility open in Mountain View.

April 28, 2009
Perlegen Builds Commercial Group to Support Upcoming MammaPLUS™ Launch
Industry veterans will introduce breast cancer risk stratifier to help physicians determine monitoring and treatment plans for women with intermediate levels of risk.

April 23, 2009
Perlegen Out-Licenses Genetic Diagnostics Intellectual Property to Celera
Genetic analysis patents and cardiac genetic markers may be key to development of new
Celera tests.